Mermoud André

Governatori Lorenzo, Oliverio Leandro, Mermoud André, Scampoli Alessandra, Sarati Federica, Carradori Andrea et al.

This meta-analysis found trabeculectomy more effective for uncontrolled glaucoma, but PreserFlo had less visual field progression and lower hypotony risk, making it suitable for sensitive patients.

Merlo Pich Francesco Giorgio, Oliverio Leandro, Gillmann Kevin, Mermoud André

This study found that NPDS and PDS surgeries for open-angle glaucoma achieve similar IOP reduction, but NPDS offers a superior safety profile with faster visual recovery and fewer complications, making it a safer option.

Roy Sylvain, Mermoud André

This 2-year study found the adjustable eyeWatch device effectively lowered IOP and medication use in refractory glaucoma, offering a safe, sustained treatment option.

Torbey Julien, Paillard Archibald, Rao Harsha L, Gillman Kevin, Bravetti Giorgio E, Mermoud André et al.

XEN 45 gel stent implantation for open-angle glaucoma showed safe, sustained IOP and medication reduction over 5 years, offering a valuable long-term treatment option for patients.

Gillmann Kevin, Meduri Enrico, Paillard Archibald, Bravetti Giorgio E, Rao Harsha L, Mermoud André et al.

This study found bilateral deep sclerectomy outcomes are linked; success in the first eye significantly increases the odds of success in the second eye by 6-fold.

Gillmann Kevin, Mermoud André

Gillmann Kevin, Meduri Enrico, Niegowski Laëtitia J, Mermoud André

This review found PEXG is aggressive and needs early diagnosis. Surgery, including cataract extraction and various glaucoma procedures, offers IOP reduction, but more comparative studies are needed for optimal management.

Meduri Enrico, Gillmann Kevin, Bravetti Giorgio E, Niegowski Letitia J, Mermoud André, Weinreb Robert N et al.

This study used SS-OCT to measure the anterior chamber angle in narrow-angle eyes before and after laser iridotomy. It found LPI significantly widened the angle, confirming SS-OCT's utility for assessing angle-closure glaucoma treatment.

Gillmann Kevin, Bravetti Giorgio Enrico, Rao Harsha L, Mermoud André, Mansouri Kaweh

XEN gel stent implantation significantly lowered IOP and medication use at 3 years for glaucoma, despite needing frequent revisions. Identifying high-risk patients preoperatively is crucial.

Gillmann Kevin, Mansouri Kaweh, Ambresin Aude, Bravetti Giorgio E, Mermoud André

iStent inject outcomes were studied for 12 months. Key findings: device protrusion and Schlemm's canal dilation predict success, devices remain stable. Clinical relevance: guides surgical technique for better glaucoma control.

Gillmann Kevin, Bravetti Giorgio E, Rao Harsha L, Mermoud André, Mansouri Kaweh

This study found bilateral XEN stent outcomes are linked: success in the first eye predicts 16-fold higher success in the second eye, guiding patient counseling and surgical planning.

Bravetti Giorgio Enrico, Mansouri Kaweh, Gillmann Kevin, Rao Harsha L, Mermoud André

XEN-augmented Baerveldt implants moderately reduced IOP in refractory glaucoma, but 41.5% required reoperation within a year, indicating limited long-term success despite initial IOP reduction.

Niegowski Laëtitia J, Bravetti Giorgio E, Gillmann Kevin, Mansouri Kaweh, Mermoud André

Tutoplast pericardium grafts effectively repaired leaky or uncomfortable blebs after glaucoma surgery, improving eye pressure and symptoms in most patients for at least six months.

Roy Sylvain, Villamarin Adan, Stergiopulos Constantinos, Bigler Stéphane, Stergiopulos Nikolaos, Wachtl Josephine et al.

This study compared eyeWatch and Ahmed valves for refractory glaucoma, finding eyeWatch offered better success rates and IOP control, likely due to its postoperative adjustability.

Gillmann Kevin, Bravetti Giorgio E, Rao Harsha L, Mermoud André, Mansouri Kaweh

This study compared corneal endothelial cell loss after combined XEN gel stent and phacoemulsification versus phacoemulsification alone. It found similar, non-significant cell loss, suggesting XEN combined with phacoemulsification is safe for corneal endothelium.

Elahi Sina, Bravetti Giorgio E, Gillmann Kevin, Villamarin Adan, Meeus Léopold, Stergiopoulos Nikos et al.

An EyeWatch device successfully rescued chronic low eye pressure after a Baerveldt implant, offering a new way to non-invasively manage post-surgical hypotony and improve patient outcomes.

Midha Neha, Gillmann Kevin, Chaudhary Ankita, Mermoud André, Mansouri Kaweh

This study found mitomycin C-augmented needling effectively lowers IOP in failing XEN blebs, providing a safe, durable solution to restore filtration and reduce the need for further surgery.

Ch'ng Tun Wang, Gillmann Kevin, Hoskens Kirsten, Rao Harsha L, Mermoud André, Mansouri Kaweh

Glaucoma surgery improved macular microcirculation with a delayed response, while peripapillary vessels were IOP-independent. FAZ parameters show promise for assessing vascular reperfusion post-surgery.

Gillmann Kevin, Bravetti Giorgio E, Mermoud André, Rao Harsha L, Mansouri Kaweh

This study found the XEN gel stent is equally safe and effective for pseudoexfoliative and primary open-angle glaucoma, offering similar IOP reduction and success rates, which is clinically relevant for managing both conditions.

Gillmann Kevin, Bravetti Giorgio E, Mermoud André, Mansouri Kaweh

This study found iStent inject protrusion into the anterior chamber and Schlemm's canal dilation correlate with lower post-operative IOP, highlighting optimal positioning for glaucoma surgery.

Gillmann Kevin, Bravetti Giorgio E, Mermoud André, Mansouri Kaweh

XEN stent dislocation into the anterior chamber can occur, with eye movement causing corneal contact. This leads to significant, localized corneal endothelial cell loss, highlighting a critical safety concern.

Bravetti Giorgio E, Gillmann Kevin, Mansouri Kaweh, Mermoud André

This case links congenital glaucoma to Kabuki Syndrome, showing these patients require glaucoma drainage devices and intensive anti-inflammatory therapy due to high surgical risks.

Roy Sylvain, Villamarin Adan, Stergiopulos Constantinos, Bigler Stéphane, Guidotti Jacopo, Stergiopulos Nikolaos et al.

This study found the adjustable eyeWatch device effectively controlled IOP and reduced medications in refractory glaucoma, allowing non-invasive post-operative adjustments to prevent hypotony and reinterventions.

Mansouri Kaweh, Gillmann Kevin, Rao Harsha L, Guidotti Jacopo, Mermoud André

This study found the XEN gel implant similarly effective and safe for reducing eye pressure in both pseudoexfoliative and primary open-angle glaucoma, making it a viable treatment option for both conditions.

Midha Neha, Rao Harsha L, Mermoud André, Mansouri Kaweh

This study found lower day 1 post-op IOP predicts less needling after standalone XEN implants. Clinically, early intervention via needling is crucial if IOP is high after standalone XEN.